Legionella pneumophila
Jump to navigation
Jump to search
Introduction
Etiologic agent of Legionnaire's disease.
Epidemiology
- accounts for 85% of Legionella pneumonia Risk factors: (see Legionella)
Genetics
- stop codon polymorphism in position 352 of TLR5 results in individuals unable to mediate flagellin signaling
- expressed in dominant fashion
Clinical manifestations
Laboratory
- Legionella pneumophila serology
- Legionella pneumophila serogroup
- at least 14 serotypes 1-14
- Legionella pneumophila antigen in tissue/body fluid
- Legionella pneumophila DNA
- also see Legionnaire's disease
- also see Legionella for other diagnostic laboratory studies
- see ARUP consult[6]
Radiology
Management
More general terms
Additional terms
- Legionella DNA
- Legionella identified by culture
- Legionnaire's disease
- Toll-like receptor 5; Toll/interleukin-1 receptor-like protein 3 (TLR5, TIL3)
References
- ↑ Manual of Medical Therapeutics, 28th edition, Ewald & McKenzie (eds) Little, Brown & Co, 1995, pg 302
- ↑ Harrison's Principles of Internal Medicine, 13th ed. Companion Handbook, Isselbacher et al (eds), McGraw-Hill Inc. NY, 1995, pg 228-29
- ↑ Mayo Internal Medicine Board Review, 1998-99, Prakash UBS (ed) Lippincott-Raven, Philadelphia, 1998, pg 797
- ↑ Medical Knowledge Self Assessment Program (MKSAP) 11, American College of Physicians, Philadelphia 1998
- ↑ Journal Watch 25(8):63-64, 2005 Blazquez Garrido RM, Espinosa Parra FJ, Alemany Frances L, Ramos Guevara RM, Sanchez-Nieto JM, Segovia Hernandez M, Serrano Martinez JA, Huerta FH. Antimicrobial chemotherapy for legionnaires disease: levofloxacin versus macrolides. Clin Infect Dis. 2005 Mar 15;40(6):800-6. Epub 2005 Feb 17. PMID: https://www.ncbi.nlm.nih.gov/pubmed/15736011
- ↑ 6.0 6.1 ARUP Consult: Legionella pneumophila The Physician's Guide to Laboratory Test Selection & Interpretation https://www.arupconsult.com/content/legionella-pneumophila